---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065190"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:49:57.895946+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M

## Summary
- Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
- Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.
- Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.
- Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.
- Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline.

## SEC filing metadata
- accession: 0001193125-26-065190
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/0001193125-26-065190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/fulc-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065190
- JSON: https://secwatch.observer/filing/0001193125-26-065190.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.